$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
Pharmaceutical industry roundup of 2014
Firm will split off its biopharmaceuticals business from medical products
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud